Bacman Sandra R, Williams Sion L, Pinto Milena, Moraes Carlos T
Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA.
Department of Neurology, University of Miami School of Medicine, Miami, Florida, USA.
Methods Enzymol. 2014;547:373-97. doi: 10.1016/B978-0-12-801415-8.00018-7.
For more than a decade, mitochondria-targeted nucleases have been used to promote double-strand breaks in the mitochondrial genome. This was done in mitochondrial DNA (mtDNA) homoplasmic systems, where all mtDNA molecules can be affected, to create models of mitochondrial deficiencies. Alternatively, they were also used in a heteroplasmic model, where only a subset of the mtDNA molecules were substrates for cleavage. The latter approach showed that mitochondrial-targeted nucleases can reduce mtDNA haplotype loads in affected tissues, with clear implications for the treatment of patients with mitochondrial diseases. In the last few years, designer nucleases, such as ZFN and TALEN, have been adapted to cleave mtDNA, greatly expanding the potential therapeutic use. This chapter describes the techniques and approaches used to test these designer enzymes.
十多年来,线粒体靶向核酸酶一直被用于促进线粒体基因组中的双链断裂。这是在线粒体DNA(mtDNA)同质性系统中进行的,在该系统中所有mtDNA分子都可能受到影响,以创建线粒体缺陷模型。另外,它们也被用于异质性模型,其中只有一部分mtDNA分子是切割的底物。后一种方法表明,线粒体靶向核酸酶可以降低受影响组织中的mtDNA单倍型负荷,这对线粒体疾病患者的治疗具有明确的意义。在过去几年中,诸如锌指核酸酶(ZFN)和转录激活因子样效应物核酸酶(TALEN)等定制核酸酶已被改造用于切割mtDNA,极大地扩展了潜在的治疗用途。本章描述了用于测试这些定制酶的技术和方法。